Fahn, S. The spectrum of levodopa-induced dyskinesias. Ann Neurol
Riley, DE, Lang, AE. The spectrum of levodopa-related fluctuationsin Parkinson’s disease. Neurology
Hillen, ME, Sage, JI. Nonmotor fluctuations in patients with Parkinson’s disease. Neurology
Witjas, T, Kaphan, E, Azulay, JP, et al.
Nonmotor fluctuations in Parkinson’sdisease: frequentand disabling. Neurology
Papa, SM, Engber, TM, Kask, AM, Chase, TN. Motor fluctuations inlevodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res
Merello, M, Lees, AJ. Beginning-of-dose motor deteriorationfollowing the acute administration of levodopa and apomorphine in Parkinson’s disease. J Neurol Neurosurg Psychiatry
Blanchet, PJ, Allard, P, Grégoire, L, et al.
Risk factors for peak dosedyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci
Muenter, MD, Sharpless, NS, Tyce, GM, Darley, FL. Patterns ofdystonia (“I-D-I” and “D-I-D”) in response to L-dopa therapy for Parkinson’s disease. Mayo Clin Proc
Marconi, R, Lefebvre-Caparros, D, Bonnet, AM, et al.
Levodopa-induced dyskinesias in Parkinson’s disease. Phenomenology and pathophysiology. Mov Disord
Togasaki, DM, Tan, L, Protell, P, et al.
Levodopa induces dyskinesiasin normal squirrel monkeys. Ann Neurol
Daras, M, Koppel, BS, Atos-Radzion, E. Cocaine-inducedchoreoathetoid movements (“crack dancing”). Neurology
de la Fuente-Fernandez, R, Pal, PK, Vingerhoets, FJG, et al.
Evidencefor impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. J Neural Transm
de la Fuente-Fernandez, R, Lu, J-Q, Sossi, V, et al.
Biochemicalvariations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover. Ann Neurol
Blanchet, PJ, Grondin, R, Bédard, PJ. Dyskinesia and wearing-offfollowing dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Mov Disord
Nutt, JG, Carter, JH, Lea, ES, Sexton, GJ. Evolution of the response tolevodopa during the first 4 years of therapy. Ann Neurol
Rascol, A, Guiraud, B, Montastruc, JL, David, J, Clanet, M. Long-termtreatment of Parkinson’s disease with bromocriptine. J NeurolNeurosurg Psychiatry
Lees, AJ, Stern, GM. Sustained bromocriptine therapy in previouslyuntreated patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry
Hely, MA, Morris, JGL, Reid, WGJ, et al.
The Sydney MulticentreStudy of Parkinson’s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry
Bedard, PJ, Di Paolo, T, Falardeau, P, Boucher, R. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperonebinding. Brain Res
Blanchet, P, Bédard, PJ, Britton, DR, Kebabian, JW. Differential effectof selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Therap
Muriel, M-P, Bernard, V, Levey, AI, et al.
Levodopa induces acytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson’s disease. Ann Neurol
Gomez-Mancilla, B, Bédard, PJ. Effect of D1 and D2 agonists andantagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J PharmacolExp Ther
Engber, TM, Susel, Z, Juncos, JL, et al.
Continuous and intermittentlevodopa differentially affect rotation induced by D1 and D2 dopamine agonists. Eur J Pharmacol
Engber, TM, Susel, Z, Kuo, S, et al.
Levodopa replacement therapyalters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res
Henry, B, Crossman, AR, Brotchie, JM. Effect of repeated L-DOPA,bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol
Blanchet, PJ, Calon, F, Martel, J-C, et al.
Continuous administrationdecreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Therap
Blanchet, PJ, Grondin, R, Bédard, PJ, et al.
Dopamine D1 receptordesensitization profile in MPTP-lesioned primates. Eur J Pharmacol
Mouradian, MM, Heuser, IJE, Baronti, F, Chase, TN. Modification ofcentral dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson’s disease. Ann Neurol
Blanchet, PJ, Calon, F, Morissette, M, et al.
Regulation of dopaminereceptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTPprimate model. In: Calne, D, Calne, SM, (Eds). Parkinson’s Disease: Advances in Neurology, vol. 86, Philadelphia, Lippincott Williams & Wilkins, 2001: 337–344.
Herrero, MT, Augood, SJ, Asensi, H, et al.
Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. Mol Brain Res
Turjanski, N, Lees, AJ, Brooks, DJ. In vivo studies on striataldopamine D1 and D2 site binding in L-dopa-treated Parkinson’s disease patients with and without dyskinesias. Neurology
Bordet, R, Ridray, S, Carboni, S, et al.
Induction of dopamine D3receptor expression as a mechanism of behavioral sensitization tolevodopa. Proc Natl Acad Sci USA
Hurley, MJ, Stubbs, CM, Jenner, P, Marsden, CD. D3 receptorexpression within the basal ganglia is not affected by Parkinson’s disease. Neurosci Lett
Ryoo, HL, Pierrotti, D, Joyce, JN. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson’s disease. Mov Disord
Calon, F, Goulet, M, Blanchet, PJ, et al.
Levodopa or D2 agonistinduced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex. Brain Res
Calon, F, Morissette, M, Goulet, M, et al.
125I-CGP64213 binding toGABAB receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments. Exp Neurol
Mitchell, IJ, Boyce, S, Sambrook, MA, Crossman, AR. A 2 -deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Brain
Soghomonian, J-J, Pedneault, S, Blanchet, PJ, et al.
L-dopa regulatesglutamate decarboxylases mRNA levels in MPTP-treated monkeys. Molec Brain Res
Laitinen, LV, Bergenheim, AT, Hariz, MI. Leksell’s posteroventralpallidotomy in the treatment of Parkinson’s disease. J Neurosurg
Baron, MS, Vitek, JL, Bakay, RA, et al.
Treatment of advancedParkinson’s disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol
Lang, AE, Lozano, AM, Montgomery, E, et al.
Posteroventral medialpallidotomy in advanced Parkinson’s disease. N Engl J Med
Volkmann, J, Sturm, V, Weiss, P, et al.
Bilateral high-frequencystimulation of the internal globus pallidus in advanced Parkinson’s disease. Ann Neurol
Krack, P, Pollak, P, Limousin, P, et al.
Inhibition of levodopa effectsby internal pallidal stimulation. Mov Disord
Kumar, R, Lang, AE, Rodriguez-Oroz, MC, et al.
Deep brainstimulation of the globus pallidus pars interna in advanced Parkinson’s disease. Neurology
2000;55(12 suppl 6):S34-S39.
Duty, S, Brotchie, JM. Enhancement of the behavioral response toapomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Exp Neurol
Piccini, P, Weeks, RA, Brooks, DJ. Alterations in opioid receptorbinding in Parkinson’s disease patients with levodopa-induceddyskinesias. Ann Neurol
Henry, B, Fox, SH, Crossman, AR, Brotchie, JM. µ- and δ-opioidreceptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Exp Neurol
Henry, B, Brotchie, JM. Potential of opioid antagonists in thetreatment of levodopa-induced dyskinesias in Parkinson’s disease. Drugs Aging
Chase, TN, Engber, TM, Mouradian, MM. Contribution ofdopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson’s disease. In: Battistin, L, Scarlato, G, Caraceni, T, Ruggieri, S, (Eds). Advances in Neurology, vol 69: Drugs for the Treatment of Parkinson’s disease. Philadelphia: Lippincott-Raven, 1996;62: 497–501.
Brotchie, JM. Advances in understanding the neural mechanismsunderlying L-dopa-induced dyskinesia. In: Stern, GM, (Ed.) Parkinson’sDisease. Advances in Neurology, Vol. 80. Philadelphia: Lippincott Williams & Wilkins
Calon, F, Morissette, M, Ghribi, O, et al.
Alteration of glutamatereceptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry
Papa, SM, Chase, TN. Levodopa-induced dyskinesias improved by aglutamate antagonist in Parkinsonian monkeys. Ann Neurol
Blanchet, PJ, Konitsiotis, S, Whittemore, ER, et al.
Differing effectsof N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther
Konitsiotis, S, Blanchet, PJ, Verhagen, L, Lamers, E, Chase TN.AMPA receptor blockade improves levodopa-induced dyskinesiain MPTPmonkeys. Neurology
Verhagen Metman, L, Del Dotto, P, van den Munckhof, P, et al.
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology
Oh, JD, Vaughan, CL, Chase, TN. Effect of dopamine denervationand dopamine agonist administration on serine phosphorylationof striatal NMDAreceptor subunits. Brain Res
Marin, C, Papa, SM, Engber, TM, et al.
MK801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res
Doucet, J-P, Nakabeppu, Y, Bédard, PJ, et al.
Chronic alterations indopaminergic neurotransmission produce a persistent elevation of AFosB-like protein(s) in both rodent and primate striatum. Eur J Neurosci
Andersson, M, Hilbertson, A, Cenci, MA. Striatal fosB expression iscausally linked with L-dopa-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson’s disease. Neurobiol Dis
Brotchie, JM. Adjuncts to dopamine replacement: a pragmaticapproach to reducing the problem of dyskinesia in Parkinson’s disease. Mov Disord
Sieradzan, KA, Fox, SH, Hill, M, et al.
Cannabinoids reducelevodopa-induced dyskinesia in Parkinson’s disease: a pilot study. Neurology
Brotchie, JM. The neural mechanisms underlying levodopa-induceddyskinesia in Parkinson’s disease. Ann Neurol
Bibbiani, F, Oh, JD, Chase, TN. Serotonin 5-HT1A agonist improvesmotor complications in rodent and primate parkinsonian models. Neurology
Grondin, R, Bédard, PJ, Hadj Tahar, A, et al.
Antiparkinsonian effectof a new selective adenosine A2a receptor antagonist in MPTP-treated monkeys. Neurology
Filion, M, Tremblay, L, Bédard, PJ. Effects of dopamine agonists onthe spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res
Papa, SM, Desimone, R, Fiorani, M, Oldfield, EH. Internal globuspallidus discharge is nearly suppressed during levodopa-induceddyskinesias. Ann Neurol
Albin, R, Young, A, Penney, J. The functional anatomy of basalganglia disorders. Trends Neurosci
Hutchison, WD, Levy, R, Dostrovsky, JO, et al.
Effects ofapomorphine on globus pallidus neurons in parkinsonianpatients. Ann Neurol
Obeso, JA, Rodriguez-Oroz, MC, Rodriguez, M, et al.
Pathophysiology of levodopa-induced dyskinesias in Parkinson’s disease: problems with the current model. Ann Neurol
Filion, M. Physiologic basis of dyskinesia. Ann Neurol
Benabid, AL, Benazzouz, A, Limousin, P, et al.
Dyskinesias and thesubthalamic nucleus. Ann Neurol
Caparros-Lefebvre, D, Blond, S, Feltin, MP, Pollak, P, Benabid, AL. Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex. J Neurol Neurosurg Psychiatry